| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 150% | HC Wainwright & Co. | → $2 | Reiterates | Buy → Buy |
| 06/07/2023 | 25% | Jefferies | → $1 | Upgrades | Underperform → Hold |
| 05/15/2023 | 150% | HC Wainwright & Co. | $6 → $2 | Maintains | Buy |
| 05/08/2023 | 650% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 04/12/2023 | 650% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 04/06/2023 | 650% | HC Wainwright & Co. | $14 → $6 | Maintains | Buy |
| 03/15/2023 | 1025% | Oppenheimer | $14 → $9 | Maintains | Outperform |
| 02/14/2023 | 1650% | Oppenheimer | $20 → $14 | Maintains | Outperform |
| 02/10/2023 | 1650% | HC Wainwright & Co. | $18 → $14 | Maintains | Buy |
| 12/07/2022 | 2150% | HC Wainwright & Co. | $21 → $18 | Maintains | Buy |
| 12/05/2022 | 2650% | Cantor Fitzgerald | $30 → $22 | Maintains | Overweight |
| 11/10/2022 | 2525% | HC Wainwright & Co. | $24 → $21 | Maintains | Buy |
| 05/18/2022 | 3775% | Brookline Capital | $29 → $31 | Maintains | Buy |
| 05/13/2022 | 6775% | Jefferies | $33 → $55 | Maintains | Buy |
| 04/12/2022 | 4400% | Oppenheimer | $25 → $36 | Maintains | Outperform |
| 04/12/2022 | 2900% | HC Wainwright & Co. | $21 → $24 | Maintains | Buy |
| 04/13/2021 | 2275% | Jefferies | → $19 | Initiates Coverage On | → Buy |
| 02/24/2021 | 2525% | HC Wainwright & Co. | $22 → $21 | Maintains | Buy |
| 02/11/2021 | 2650% | HC Wainwright & Co. | $17 → $22 | Maintains | Buy |
| 02/09/2021 | 2025% | HC Wainwright & Co. | $12 → $17 | Maintains | Buy |
| 12/16/2020 | 2275% | Oppenheimer | $9 → $19 | Maintains | Outperform |
| 12/15/2020 | 1400% | HC Wainwright & Co. | $8 → $12 | Maintains | Buy |
| 12/14/2020 | 1775% | Cantor Fitzgerald | $6 → $15 | Maintains | Overweight |
| 12/10/2020 | 900% | HC Wainwright & Co. | $6 → $8 | Maintains | Buy |
| 05/14/2020 | 1025% | Oppenheimer | $8 → $9 | Maintains | Outperform |
| 01/21/2020 | 650% | HC Wainwright & Co. | $4.5 → $6 | Reinstates | → Buy |
| 07/30/2019 | 1400% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 07/02/2019 | 650% | Cantor Fitzgerald | → $6 | Initiates Coverage On | → Overweight |
| 03/19/2019 | 525% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
What is the target price for Veru (VERU)?
The latest price target for Veru (NASDAQ: VERU) was reported by HC Wainwright & Co. on September 27, 2023. The analyst firm set a price target for $2.00 expecting VERU to rise to within 12 months (a possible 150.00% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Veru (VERU)?
The latest analyst rating for Veru (NASDAQ: VERU) was provided by HC Wainwright & Co., and Veru reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Veru (VERU)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veru, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veru was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
Is the Analyst Rating Veru (VERU) correct?
While ratings are subjective and will change, the latest Veru (VERU) rating was a reiterated with a price target of $0.00 to $2.00. The current price Veru (VERU) is trading at is $0.80, which is within the analyst's predicted range.